Sartorius Stedim Biotech confirms 2026 guidance and refines capex ratio
FROM THE WIRE · SEEKINGALPHA.COM
* Sartorius Stedim Biotech S.A. press release [https://www.sartorius.com/en/company/sartorius-stedim-biotech-sa-investor-relations] (SDMHF [https://seekingalpha.com/symbol/SDMHF]): 9M Non-GAAP EPS of €2.84. * Revenue of €2.29B (+4.1% Y/Y). * Guidance for fiscal year 2026…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralResults and guidance confirmed, an ordinary-flow update for a mid-cap stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Nine-month non-GAAP EPS is 2.84 euros.
- 02Revenue is 2.29 billion euros, up 4.1% year over year.
- 03The company expects constant-currency sales growth of around 6 to 10%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Sartorius Stedim Biotech S.A.234.29 USDAwaiting tradestoday -0.30%Neutral Sartorius Stedim Biotech S.A.24.78 USD+2.42%today +2.42%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets